Device Trial Radar · NCT06011551
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Jan 13, 2025
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- ReGelTec, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-center, prospective, dual arm, randomized, controlled pivotal study to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL™ System.
Conditions
- Degenerative Disc Disease (DDD)
Interventions
The ReGelTec HYDRAFIL™ SystemDevice
The ReGelTec HYDRAFIL System is designed to deliver an injectable hydrogel implant (the HYDRAFIL implant) for the treatment of a degenerative lumbar disc.
Conservative Care ManagementOther
Conservative care management (including physical therapy and/or pain medication)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Endpoint of Clinical SuccessTime frame: 12-month
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Alabama Clinical Therapeutics
Birmingham, Alabama · Recruiting
Source Healthcare
Santa Monica, California · Recruiting
Boomerang Healthcare (IPM Medical Group)
Walnut Creek, California · Recruiting
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.